Company Overview - Victory Square Technologies Inc. is a venture builder providing investors access to a diverse portfolio of next-generation technology companies [2][23] - The company operates a business model focused on buying, building, and investing in early-stage tech companies, with a commitment to support them for up to 48 months before they can stand on their own [24][26] Financial Performance - For the first half of 2025, adjusted revenue reached $13.87 million, a 27% increase from $10.97 million in the first half of 2024 [7] - Q2 2025 revenue was $5.38 million, compared to $4.43 million in Q2 2024, marking a 21% year-over-year growth [7] - Adjusted EBITDA for the first half of 2025 was $463 thousand, a significant improvement from a loss of $1.59 million in the first half of 2024 [7] Portfolio Highlights - Victory Square maintains over 25 portfolio companies across sectors including digital health, AI, gaming, climate tech, and pet wellness [5][6] - Hydreight Technologies, a key portfolio company, reported a six-month adjusted revenue of $13.9 million, reflecting a 33% year-over-year growth and achieved its third consecutive profitable quarter [6][8] - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early preclinical trials showing promising results [10][11] Strategic Initiatives - The company is exploring share buybacks to reduce net asset value (NAV) discount and enhance shareholder value [6][16] - Pawsible Ventures, another portfolio company, is focused on pet wellness and telehealth solutions, with plans to launch a fund and incubator program in fall 2025 [12][15] Industry Context - The global diabetes therapeutics market is projected to grow to $118 billion by 2032, with over 500 million people currently living with diabetes [13] - The global pet care market is expected to reach $368 billion by 2030, indicating significant growth potential in the pet wellness sector [14] Future Outlook - The company aims to continue supporting Hydreight's growth, advance Insu Therapeutics towards regulatory milestones, and launch Pawsible Ventures' fund and incubator program [20][21] - Upcoming investor conferences will feature Victory Square and its portfolio companies, providing opportunities for engagement with investors [21]

VANCOUVER, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS | OTCQB: HYDTF | FSE: SO6) ("Hydreight" or the "Company"), a telehealth and mobile medical company operating across the U.S. focused on expanding access to care, is pleased to announce it has been invited to participate in the Canaccord Genuity 45th Annual Growth Conference, taking place in Boston, Massachusetts on August 12 and 13, 2025. The CG Growth Conference is a well-recognized investment event conne ...

Core Viewpoint - Victory Square Technologies Inc. reported solid financial results for Q1 2025 and emphasized its strategic focus on the digital health and wellness sectors, identifying significant growth opportunities in a fragmented healthcare market [4][11]. Financial Highlights - Adjusted Revenue for Q1 2025 was $6.528 million, while GAAP Revenue stood at $4.540 million. The Cost of Goods Sold (COGS) was $3.036 million, resulting in a Gross Margin of $1.504 million. As of March 31, 2025, the company had Cash & Marketable Securities amounting to $9.698 million [7]. Business Focus Areas - The company aims to scale its holdings in the digital health sector, particularly through its flagship portfolio company, Hydreight Technologies, which provides a compliant platform for healthcare services across the U.S. [4][8]. - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early trials showing promising results in insulin uptake [8][14]. - Pawsible Ventures is focused on pet wellness and telehealth, leveraging trends in human healthcare, with the global pet care market projected to reach $368 billion by 2030 [10][14]. Portfolio Management - Victory Square actively manages its portfolio, having sold certain AI fintech solutions for approximately $880,000 in equity consideration in Q1 2025. This follows a previous sale of BlockX for about $1.7 million in listed shares [11][15]. Industry Context - The U.S. healthcare spending exceeds $4.5 trillion annually and is projected to reach $7 trillion by 2031, highlighting the sector's fragmentation and potential for value creation [4]. - The global diabetes therapeutics market is expected to reach $118 billion by 2032, with over 500 million people currently living with diabetes [14]. Upcoming Events - Victory Square will host an Investor Webinar on July 17, 2025, to provide updates and address investor questions [12]. Leadership and Strategy - The leadership team at Insu Therapeutics includes experienced professionals from academia and the pharmaceutical industry, indicating a strong foundation for advancing its clinical milestones [14]. - The company’s business model focuses on buying, building, and investing in early-stage tech companies, with a commitment to supporting their growth for up to 48 months [17].

Core Insights - Hydreight Technologies Inc. has launched a direct-to-consumer genetic testing and personalized wellness solution through its VSDHOne platform, expanding access to precision-based care [1][2][8] Group 1: Product Offering - The new offering allows patients to access at-home DNA testing kits and receive personalized health plans based on their genetic profiles, including insights on nutrition, fitness, supplementation, and medication compatibility [2][5] - Key features of the offering include at-home DNA swab kits, lab-based genetic sequencing, personalized health recommendations, and consultations with licensed prescribers [11][12] Group 2: Market Positioning - The launch positions Hydreight's extensive network of over 3,000 nurses, 200 physicians, and 400 direct-to-consumer brands to provide this service, enhancing revenue and patient retention through personalized care [4][7] - The global consumer genomics market is projected to exceed $50 billion by 2030, with the at-home testing market expected to surpass $15 billion by 2028, indicating strong growth potential for Hydreight's new offering [6] Group 3: Business Model - The offering is structured around a subscription-based model, generating upfront revenue from testing and recurring monthly revenue from tailored health regimens and supplement delivery [9] - The integration into the VSDHOne platform allows for immediate embedding of genetic testing into existing offerings, driving higher customer retention and lifetime value [9] Group 4: Strategic Goals - Hydreight's genetic testing initiative aligns with its 2025 priorities, which include expanding high-margin white-label services, scaling onboarding of licensed direct-to-consumer brands, and launching new wellness categories [10][16]